Grufity logoGrufity logo

HOLX

74.22USD-0.89(-1.18%)Market Closed

Hologic Inc

Market Summary

USD74.22-0.89Market Closed
-1.18%

HOLX Alerts

HOLX Stock Price

RSI Chart

Valuation

Market Cap

16.7B

Price/Earnings

11.05

Price/Sales

3.2

Price/Cashflow

6.9

MarketCap/EBT

9.01

Price/Sales

Profitability

EBT Margin

35.50%

Return on Equity

30.25%

Return on Assets

16.16%

Fundamentals

Revenue

Revenue (TTM)

4.9B

Revenue Y/Y

-27.6%

Revenue Q/Q

-4.94%

Earnings

Earnings (TTM)

1.3B

Earnings Y/Y

-63.9%

Earnings Q/Q

-48.03%

Price Action

52 Week Range

59.7880.49
(Low)(High)

Last 7 days

-0.2%

Last 30 days

-1.3%

Last 90 days

9.6%

Trailing 12 Months

-0.3%

Financial Health

Current Ratio

3.91

Debt/Equity

0.56

Debt/Cashflow

0.86

Investor Care

Buy Backs (1Y)

1.51%

Diluted EPS (TTM)

5.13

Peers (Alternatives to Hologic)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
10.2T
429.9M
-15.19% 31.17%
185.5K
28.0K
144.70% 331.94%
115.4B
30.8B
-8.94% -28.67%
22.17
3.71
-3.11% -8.14%
86.7B
17.9B
11.64% -6.61%
41.71
4.92
7.67% 29.32%
86.3B
6.1B
11.18% -17.75%
62.6
14.1
11.47% -18.42%
67.1B
18.9B
10.66% 2.81%
38.21
3.25
-6.81% -14.96%
43.9B
5.4B
5.44% -35.45%
30.09
8.18
5.29% -1.25%
MID-CAP
6.7B
998.4M
9.55% 2.62%
44.21
6.87
6.04% -19.01%
6.4B
806.4M
33.31% -13.25%
-331.15
7.96
20.10% -221.96%
3.9B
380.1M
-6.98% -2.00%
-29.57
10.69
18.85% -63.58%
3.6B
790.7M
14.84% -68.69%
-273.58
4.7
19.65% -412.22%
SMALL-CAP
1.6B
126.8M
23.76% 23.16%
-26.38
14.01
34.44% -10.05%
1.0B
795.9M
15.03% -14.89%
-131.34
1.33
8.11% 182.50%
994.0M
154.8M
3.15% -46.03%
-10.57
6.72
60.29% -2309.58%
606.7M
236.2M
-5.60% -30.91%
-16.43
2.57
-8.79% -175.19%

Financials for Hologic

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-7.0%4,8635,2265,3925,4945,632
Gross Profit-9.5%2,9973,3113,4633,6023,796
Operating Expenses-1.1%1,3571,3721,4291,3661,316
  S&GA Expenses0.0%630630621581561
  R&D Expenses-0.2%283284288290276
Earnings Before Taxes-14.4%1,5881,8551,9442,1512,361
Net Income-13.9%1,3021,5121,5521,7161,870
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-3.1%9,0719,3579,5159,2858,920
  Current Assets-1.2%3,8623,9093,8813,5063,169
    Cash Equivalents-1.5%2,3402,3752,2911,4211,170
  Inventory7.3%624581526518501
  Net PPE-1.7%482490507554565
  Goodwill-1.5%3,2373,2863,3173,3293,282
  Current Liabilities-6.3%9381,0011,3051,2791,327
  Long Term Debt0.0%2,8232,8223,0703,0683,025
    LT Debt, Current100.0%158256249313
    LT Debt, Non Current-0.2%2,8082,8152,8132,8202,712
Shareholder's Equity-2.4%4,8764,9984,7934,5194,219
  Retained Earnings8.0%1,6001,4821,253798298
  Additional Paid-In Capital0.4%6,0436,0175,9975,9645,966
Accumulated Depreciation-3.5%706731721712696
Shares Outstanding-0.3%251252253--
Minority Interest------
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-12.3%2,1262,4232,7552,2452,330
  Share Based Compensation1.4%6766666565
Cashflow From Investing5.1%-206.30-217.30-965.90-1,453.20-1,329.60
Cashflow From Financing-13.1%-756.00-668.20-318.40-245.10-529.80
  Buy Backs47.7%542367555476410

Risks

What is the probability of a big loss on HOLX?

53.5%


Probability that Hologic stock will be more than 20% underwater in next one year

19.2%


Probability that Hologic stock will be more than 30% underwater in next one year.

18.5%


Probability that Hologic stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does HOLX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Hologic was unfortunately bought at previous high price.

Returns

Cumulative Returns on HOLX

14.3%


10-Year Cumulative Returns

9.7%


7-Year Cumulative Returns

12.2%


5-Year Cumulative Returns

12.1%


3-Year Cumulative Returns

What are the long-term rolling returns for HOLX?

FIve years rolling returns for Hologic.

Which funds bought or sold HOLX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
Bridgefront Capital, LLC
SOLD OFF
-100
-541,000
-
-%
2022-11-23
Toroso Investments, LLC
REDUCED
-15.78
-448,000
1,626,000
0.07%
2022-11-23
Eagle Bay Advisors LLC
UNCHANGED
-
60
2,000
-%
2022-11-22
CVA Family Office, LLC
REDUCED
-66
-12,000
5,000
-%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
7,219,000
7,219,000
0.09%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
15.99
20,000
271,000
0.01%
2022-11-22
CONTINENTAL INVESTORS SERVICES, INC.
NEW
-
869,000
869,000
0.03%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.2
-2,319,000
26,620,000
0.04%
2022-11-18
National Pension Service
REDUCED
-2.82
-2,597,000
26,753,000
0.06%
2022-11-17
M&T Bank Corp
REDUCED
-5.17
160,000
1,864,000
0.01%

1–10 of 48

Latest Funds Activity

Are funds buying HOLX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own HOLX

Hologic News

Marketscreener.com

New Data Presented at SABCS 2022 Reveal Expanded Predictive Value of the Breast Cancer Index™ Test for Ovarian Function Suppression in Premenopausal Women with HR+ Breast Cancer.12 hours ago

Marketscreener.com

Investor's Business Daily

HOLX Fair Value

Recent SEC filings of Hologic

View All Filings
Date Filed Form Type Document
Nov 17, 2022
4
Insider Trading
Nov 16, 2022
4
Insider Trading
Nov 15, 2022
10-K
Annual Report
Nov 15, 2022
S-3ASR
S-3ASR
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading

Latest Insider Trading transactions for HOLX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-30
MACMILLAN STEPHEN P
SOLD
-2,534,360
75.6527
-33,500
Chairman, President and CEO
2022-11-15
Thornal Kevin R
ACQUIRED
510,216
40.85
12,490
Group Pres, Global Diagnostics
2022-11-15
Thornal Kevin R
SOLD
-1,440,060
75.3249
-19,118
Group Pres, Global Diagnostics
2022-11-14
Griffin John M.
ACQUIRED
1,098,950
40.85
26,902
General Counsel
2022-11-14
Griffin John M.
SOLD
-2,047,890
76.124
-26,902
General Counsel
2022-11-11
Mitchell Essex D
SOLD FOR TAXES
-19,134.4
75.93
-252
Div. President, GYN Surgical
2022-11-11
MACMILLAN STEPHEN P
SOLD FOR TAXES
-7,316,240
75.93
-96,355
Chairman, President and CEO
2022-11-11
Verstreken Jan
SOLD FOR TAXES
-145,406
75.93
-1,915
Group President, International
2022-11-11
Griffin John M.
SOLD FOR TAXES
-997,796
75.93
-13,141
General Counsel
2022-11-11
COHN BENJAMIN JORDAN
SOLD FOR TAXES
-24,449.5
75.93
-322
Principal Accounting Officer

1–10 of 50

Stephen P. MacMillan
6700
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

HOLX Income Statement

2022-09-24
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Millions
12 Months Ended
Sep. 24, 2022
Sep. 25, 2021
Sep. 26, 2020
Revenues:   
Revenue from product and services$ 4,862.8$ 5,632.3$ 3,776.4
Costs of revenues:   
Amortization of acquired intangible assets295.7276.7253.2
Impairment of acquired intangible assets and equipment17.40.025.8
Gross Profit2,997.43,795.82,227.5
Operating expenses:   
Research and development283.4276.3222.5
Selling and marketing630.3561.2484.6
General and administrative407.7433.2355.7
Amortization of acquired intangible assets45.242.239.7
Impairment of acquired intangible assets and equipment27.70.04.4
Contingent consideration – fair value adjustments(39.5)(6.7)0.3
Restructuring and divestiture charges2.49.315.3
Operating expenses1,357.21,315.51,122.5
Income from operations1,640.22,480.31,105.0
Interest income12.91.44.3
Interest expense(95.1)(93.6)(116.5)
Debt extinguishment loss(0.7)(21.6)0.0
Other income (expense), net30.9(5.4)9.1
Income before income taxes1,588.22,361.11,001.9
Provision (benefit) for income taxes286.2491.4(108.6)
Net income1,302.01,869.71,110.5
Net loss attributable to noncontrolling interest (1.8)(4.7)
Net income attributable to Hologic$ 1,302.0$ 1,871.5$ 1,115.2
Net income per common share attributable to Hologic:   
Basic (in dollars per share)$ 5.18$ 7.28$ 4.24
Diluted (in dollars per share)$ 5.13$ 7.21$ 4.21
Weighted average number of shares outstanding:   
Basic (in shares)251,527257,046262,727
Diluted (in shares)253,845259,706264,613
Product   
Revenues:   
Revenue from product and services$ 4,191.2$ 4,967.3$ 3,227.0
Costs of revenues:   
Cost of goods and services sold1,166.11,205.1953.7
Service   
Revenues:   
Revenue from product and services671.6665.0549.4
Costs of revenues:   
Cost of goods and services sold$ 386.2$ 354.7$ 316.2

HOLX Balance Sheet

2022-09-24
Consolidated Balance Sheets - USD ($)
Sep. 24, 2022
Sep. 25, 2021
Current assets:  
Cash and cash equivalents$ 2,339,500,000 
Accounts receivable617,600,000$ 942,700,000
Inventory623,700,000501,200,000
Prepaid expenses and other current assets232,200,000528,800,000
Prepaid income taxes49,000,000.025,700,000
Total current assets3,862,000,0003,168,700,000
Property, plant and equipment, net481,600,000564,700,000
Intangible assets, net1,280,600,0001,659,200,000
Goodwill3,236,500,0003,281,600,000
Other assets210,500,000245,700,000
Total assets9,071,200,0008,919,900,000
Current liabilities:  
Current portion of long-term debt15,000,000.0313,000,000.0
Accounts payable197,700,000215,900,000
Accrued expenses535,300,000596,200,000
Deferred revenue186,500,000198,000,000.0
Finance lease liabilities (current)3,200,0003,700,000
Total current liabilities937,700,0001,326,800,000
Long-term debt, net of current portion2,808,400,0002,712,200,000
Finance lease liabilities (non-current)18,000,000.022,800,000
Deferred income tax liabilities90,800,000250,500,000
Deferred revenue, net of current portion9,400,00020,300,000
Other long-term liabilities330,700,000368,700,000
Commitments and contingencies (Note 13 and 14)
Stockholders’ equity:  
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued00
Common stock, $0.01 par value – 750,000 shares authorized; 298,533 and 297,306 shares issued, respectively3,000,000.03,000,000.0
Additional paid-in-capital6,042,600,0005,965,800,000
Retained earnings1,600,300,000298,300,000
Treasury stock, at cost – 51,401 and 43,653 shares, respectively(2,531,500,000)(1,989,400,000)
Accumulated other comprehensive loss(238,200,000)(59,100,000)
Total stockholders’ equity4,876,200,0004,218,600,000
Total liabilities and stockholders’ equity$ 9,071,200,000$ 8,919,900,000